CurrentCareSourcePolicy N/A

Intravenous C1‑esterase inhibitor therapy for hereditary angioedema (Berinert, Cinryze, Ruconest) — Coverage Criteria

Defines prior authorization, coverage criteria, dosing limits, and prescriber requirements for Berinert, Cinryze, and Ruconest for treatment and prophylaxis of hereditary angioedema (HAE) for CareSource members.

Policy Summary

PayerCareSource

PolicyIntravenous C1‑esterase inhibitor therapy for hereditary angioedema (Berinert, Cinryze, Ruconest) — Coverage Criteria

Policy CodePolicy N/A

Change TypeMaterial updates to continuation/initial approval pathwaysclarifications and minor editorial revisions

Effective DateN/A

Next Review DateOct 9, 2024

Key ActionSubmit prior authorization with diagnostic labs (low functional C1‑INH ≤50% and low serum C4) and prescriber documentation; approvals typically granted for 1 year.

SourceLink

POLICY UPDATE CHANGES

Clarified that a patient who previously met initial therapy criteria under the Coverage Review Department and is currently receiving the medication need only meet continuation criteria.

Added note that if prior initial therapy approval was obtained through a different entity, initial therapy criteria must be met for current review.

Deleted '[Type I or Type II]' from several indication headings for prophylaxis and acute treatment.

3brands covered

1 yeartypical approval duration

20 IU/kg

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Recommended Authorization Criteria

Berinert or Cinryze — Indications and approval logic

Approve for prophylaxis or acute treatment when diagnostic and prescriber criteria are met.

Indication: Coverage is recommended for prophylaxis or treatment of hereditary angioedema (HAE) due to C1‑INH deficiency when criteria below are met

Diagnostic criteria (required for initial therapy): Patient has HAE type I or type II as confirmed by BOTH: (a) low functional C1‑INH (≤50% of normal) at baseline as defined by laboratory reference values (documentation required); AND (b) low serum C4 at baseline as defined by laboratory reference values (documentation required)lab‑defined by reference values

Documentation required

Prescriber requirement: Medication is prescribed by or in consultation with an allergist/immunologist or physician who specializes in the treatment of HAE or related disorders

Approval pathways: A) Initial therapy: patient meets Diagnostic criteria AND Prescriber requirement; OR B) Continuation: patient has a diagnosis of HAE type I or II (documentation required), has had a favorable clinical response since initiating therapy per the prescriber (examples include decreased attack frequency, severity, or duration), AND medication is prescribed by or in consultation with an HAE specialist

If patient is currently receiving therapy but has not previously received approval through the Coverage Review Department, review under Initial Therapy criteria.

Ruconest — Indications and approval logic

Approve for treatment of acute HAE attacks when diagnostic and prescriber criteria are met.

Documentation required

Prescriber requirement: Medication is prescribed by or in consultation with an allergist/immunologist or physician who specializes in the treatment of HAE or related disorders

If patient is currently receiving therapy but has not previously received approval through the Coverage Review Department, review under Initial Therapy criteria.

Not recommended for approval

Non‑covered situations: Ruconest for prophylaxis of HAE attacks and other circumstances not listed in the Recommended Authorization Criteria

Evidence is insufficient to support Ruconest for prophylaxis; this Condition Not Recommended for Approval does not apply to Berinert or Cinryze.

Requests for use of Ruconest for prophylaxis are not recommended for approval. Ruconest is not FDA‑approved for prophylaxis of hereditary angioedema (HAE) attacks, and current evidence — including a small Phase II randomized trial — is considered insufficient to support its routine prophylactic use. This non‑recommended determination applies only to Ruconest; it does not affect prophylaxis with plasma‑derived C1‑INH products (Berinert or Cinryze).

Dosing Limits and Coding-Adjacent Limits

Ruconest single-dose limit

Maximum single-dose4,200 units (not exceeding 50 units/kg) IV

Frequency limitNo more frequently than twice daily IV

Indication contextFor treatment of acute HAE attacks when diagnostic and prescriber criteria are met

Cinryze prophylaxis dosing (patients ≥12 years)

Maximum dose (≥12 years)Up to 2,500 units (not exceeding 100 units/kg) IV

FrequencyNo more frequently than twice weekly with doses separated by ≥3 days

Indication

Authorization, Documentation, and Review Actions

Prior Authorization

Prior authorization required

Prior authorization is required for Berinert, Cinryze, and Ruconest. Approvals are typically granted for 1 year and continuation approvals require meeting continuation criteria or prior initial approval through the Coverage Review Department.

Step Therapy

Dose exception review by clinician

Requests for doses outside the established dosing in this policy will be reviewed case-by-case by a clinician (for example, the Medical Director or a Pharmacist).

Documentation Required

Required clinical and laboratory documentation

Documentation must include baseline laboratory records showing low functional C1‑INH (≤50% of normal) and low serum C4 at baseline, diagnostic documentation of HAE type I or II, and clinical notes describing clinical response when continuation approval is requested.

Clinical Background

Hereditary angioedema (HAE) due to C1‑esterase inhibitor (C1‑INH) deficiency (HAE types I/II) causes recurrent, unpredictable angioedema attacks that can be life‑threatening. Plasma‑derived C1‑INH products (Berinert, Cinryze) and recombinant C1‑INH (Ruconest) are indicated for on‑demand treatment of acute HAE attacks; Cinryze is additionally labeled for routine prophylaxis. Clinical guidelines recommend on‑demand treatment for all attacks and consideration of long‑term prophylaxis based on individual attack frequency, severity, and impact on quality of life.

Diagnostic confirmation for HAE types I/II requires laboratory evidence of low functional C1‑INH (≤50% of normal) and low serum C4 at baseline. Documentation of these baseline laboratory values is required for initial authorization reviews, and prescriber involvement by or in consultation with an allergist/immunologist or clinician experienced in HAE management is expected.

Key Definitions

HAE types I/II

Diagnostic definitionHereditary angioedema due to low C4 and low C1-INH antigenic or functional levels

Laboratory criteriaLow functional C1-INH (≤50% of normal) at baseline and low serum C4 at baseline (documentation required)

Clinical implicationFindings consistent with a diagnosis of HAE types I or II